ReviewCurrent opinion in pulmonary medicine2009
Pharmacogenetics of asthma.
Review in Current opinion in pulmonary medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Differential connectivity of gene regulatory networks distinguishes corticosteroid response in asthma.The Journal of allergy and clinical immunology · 2018Trial
- Genome-wide association study of leukotriene modifier response in asthma.The pharmacogenomics journal · 2016Trial
- Why Every Asthma Patient Tells a Different Story.Journal of clinical medicine · 2025Article
- Structure Bioinformatics of Six Human Integral Transmembrane Enzymes and their AlphaFold3 Predicted Water-Soluble QTY Analogs: Insights into FACE1 and STEA4 Binding Mechanisms.Pharmaceutical research · 2025Article
- Responsiveness of Inhaled Corticosteroid Treatment in Children with Asthma: The Role of rs242941 Polymorphism of CRHR1 Gene.Pulmonary therapy · 2023Article
- LTA4H rs2660845 association with montelukast response in early and late-onset asthma.PloS one · 2021Article
- Current Bronchodilator Responsiveness Criteria Underestimate Asthma in Older Adults.Respiratory care · 2020Article
- Genetic associations of the response to inhaled corticosteroids in asthma: a systematic review.Clinical and translational allergy · 2019Review
- Genomic Predictors of Asthma Phenotypes and Treatment Response.Frontiers in pediatrics · 2019Review
- Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.Journal of affective disorders · 2018Review
- Review
- Clinical implications of CD4Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2018Article
- Genetic and Epigenetic Components of Aspirin-Exacerbated Respiratory Disease.Immunology and allergy clinics of North America · 2016Review
- Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches.The American journal of psychiatry · 2015Review
- Genome-Wide Association Study Identifies Novel Pharmacogenomic Loci For Therapeutic Response to Montelukast in Asthma.PloS one · 2015Article
- Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter.The Journal of biological chemistry · 2014Review
- Asthma genetics and personalised medicine.The Lancet. Respiratory medicine · 2014Review
- Key role of CRF in the skin stress response system.Endocrine reviews · 2013Review
- Pharmacogenetics of asthma controller treatment.The pharmacogenomics journal · 2013Article
- Integrative systems biology approaches in asthma pharmacogenomics.Pharmacogenomics · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purpose of reviewPatient response to the asthma drug classes, bronchodilators, inhaled corticosteroids and leukotriene modifiers, are characterized by a large degree of heterogeneity, which is attributable in part to genetic variation. Herein, we review and update the pharmacogenetics and pharmaogenomics of common asthma drugs. RECENT
findingsEarly studies suggest that bronchodilator reversibility and asthma worsening in patients on continuous short-acting and long-acting beta-agonists are related to the Gly16Arg genotype for the ADRB2. More recent studies including genome-wide association studies implicate variants in other genes contribute to bronchodilator response heterogeneity and fail to replicate asthma worsening associated with continuous beta-agonist use. Genetic determinants of the safety of long-acting beta-agonist require further study. Variants in CRHR1, TBX21, and FCER2 contribute to variability in response for lung function, airways responsiveness, and exacerbations in patients taking inhaled corticosteroids. Variants in ALOX5, LTA4H, LTC4S, ABCC1, CYSLTR2, and SLCO2B1 contribute to variability in response to leukotriene modifiers. SUMMARY: Identification of novel variants that contribute to response heterogeneity supports future studies of single nucleotide polymorphism discovery and include gene expression and genome-wide association studies. Statistical models that predict the genomics of response to asthma drugs will complement single nucleotide polymorphism discovery in moving toward personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.